What is Upasita used for?

Upasita is indicated for Secondary hyperparathyroidism.

Upasita is developed by SANWA KAGAKU KENKYUSHO Co., Ltd..

What development phase is Upasita in?

Upasita is FDA-approved (marketed).

What is the generic name of Upasita?

UPACICALCET is the generic (nonproprietary) name of Upasita.

Last reviewed 2026-04-20 · How we verify

Upasita (UPACICALCET)

SANWA KAGAKU KENKYUSHO Co., Ltd. · FDA-approved active Small molecule Quality 17/100

At a glance

Generic name	UPACICALCET
Sponsor	SANWA KAGAKU KENKYUSHO Co., Ltd.
Target	Extracellular calcium-sensing receptor
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved

Approved indications

Secondary hyperparathyroidism

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Upasita CI brief — competitive landscape report
Upasita updates RSS · CI watch RSS
SANWA KAGAKU KENKYUSHO Co., Ltd. portfolio CI